Legal & General Group
CYCN icon

Legal & General Group’s Cyclerion Therapeutics CYCN Stock Holding History

Legal & General Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-98
Closed -$5K – 3527
2021
Q1 		$5K Sell
98
-901
-90% -$67.7K ﹤0.01% 3475
2020
Q4 		$61K Buy
999
+863
+635% +$58.8K ﹤0.01% 2743
2020
Q3 		$17K Sell
136
-36
-21% -$4.12K ﹤0.01% 3018
2020
Q2 		$21K Sell
172
-69
-29% -$5.77K ﹤0.01% 3046
2020
Q1 		$12K Sell
241
-63
-21% -$4.49K ﹤0.01% 3108
2019
Q4 		$16K Buy
304
+45
+17% +$4.2K ﹤0.01% 3230
2019
Q3 		$63K Sell
259
-143
-36% -$30.9K ﹤0.01% 2664
2019
Q2 		$92K Buy
+402
New +$114K ﹤0.01% 2560

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legal & General Group's CYCN Position: Q2 2021 in Review

Legal & General Group sold out of Cyclerion Therapeutics (CYCN) in Q2 2021, closing a stake of 98 shares — an estimated $5K sold.

Legal & General Group first reported a position in CYCN in Q2 2019 and held it in 8 quarters. The position peaked at $92K in Q2 2019. 67 funds tracked by Wall St. Rank hold CYCN as of Q2 2021.

  • Legal & General Group reported no remaining Cyclerion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 98 Cyclerion Therapeutics shares in Q2 2021, an estimated $5K.
  • Legal & General Group first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 8 quarters.
  • Legal & General Group's Cyclerion Therapeutics position peaked at $92K in Q2 2019.
  • 67 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.